A role for GRK2 in myocardial ischemic injury: Indicators of a potential future therapy and diagnostic

Future Cardiology

Volumn 7, Issue 4, 2011, Pages 547-556

  Brinks, Henriette ^a   Das, Amrit ^b   Koch, Walter J ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

ARKct; acute myocardial infarction; adrenergic signaling; biomarker; cardioprotection; gene therapy; GRK2; ischemia reperfusion injury

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR KINASE 1 CARBOXYL TERMINUS; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT; ENZYME INHIBITOR; G PROTEIN COUPLED RECEPTOR KINASE 2; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; CARDIOVASCULAR GENE THERAPY; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; HEART FAILURE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; ISCHEMIC PRECONDITIONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION;

BIOLOGICAL MARKERS; ENZYME INHIBITORS; G-PROTEIN-COUPLED RECEPTOR KINASE 2; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY;

EID: 79961069882     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.11.36     Document Type: Review

References (58)

1. Murray WM. Inflammation, aspirin, and the risk of cardiovascular disease. N. Engl. J. Med. 337, 422; author reply 423-424 (1997).
2. Lloyd-Jones DM. Cardiovascular risk prediction: basic concepts, current status, and future directions. Circulation 121, 1768-1777 (2010).
3. Heidenreich PA, Trogdon JG, Khavjou OA et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 123, 933-944 (2011).
4. Burns RJ, Gibbons RJ, Yi Q et al. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J. Am. Coll. Cardiol.39, 30-36 (2002). (Pubitemid 34059858)
5. Miura T, Miki T. Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy. Basic. Res. Cardiol.103, 501-513 (2008).
6. Downey JM, Cohen MV. Why do we still not have cardioprotective drugs? Circ. J. 73, 1171-1177 (2009).
7. Feldman AM, McTiernan C. New insight into the role of enhanced adrenergic receptor-effector coupling in the heart. Circulation 100, 579-582 (1999). (Pubitemid 29379744)
8. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature 415, 206-212 (2002). (Pubitemid 34059526)
9. Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB. Synergistic polymorphisms of b1-and a2C-adrenergic receptors and the risk of congestive heart failure. N. Engl. J. Med. 347, 1135-1142 (2002).
10. Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of b1-and b2-adrenergic receptors on cardiac myocytes apoptosis: role of a pertussis toxin-sensitive G protein. Circulation 100, 2210-2212 (1999).
11. Zhu WZ, Zheng M, Koch WJ, Lefkowitz RJ, Kobilka BK, Xiao RP. Dual modulation of cell survival and cell death by b(2)-adrenergic signaling in adult mouse cardiac myocytes. Proc. Natl Acad. Sci. USA 98, 1607-1612 (2001). (Pubitemid 32165546)
12. DeGeorge BR Jr, Gao E, Boucher M et al. Targeted inhibition of cardiomyocyte Gi signaling enhances susceptibility to apoptotic cell death in response to ischemic stress. Circulation 117, 1378-1387 (2008). (Pubitemid 351501491)
13. Brinks H, Boucher M, Gao E et al. Level of G-protein-coupled receptor kinase-2 determines myocardial ischemia/reperfusion injury via pro-and anti-apoptotic mechanisms. Circ. Res. 107(9), 1140-1149 (2010).
14. Brinks H, Koch WJ. bARKct: a therapeutic approach for improved adrenergic signaling and function in heart disease. J. Cardiovasc. Transl. Res. 3, 499-506 (2010).
15. Petrofski JA, Koch WJ. The b-adrenergic receptor kinase in heart failure. J. Mol. Cell. Cardiol. 35, 1167-1174 (2003). (Pubitemid 37163522)
16. Rengo G, Lymperopoulos A, Leosco D, Koch WJ. GRK2 as a novel gene therapy target in heart failure. J. Mol. Cell Cardiol. (2010) (Epub ahead of print).
17. Koch WJ, Rockman HA, Samama P et al. Cardiac function in mice overexpressing the b-adrenergic receptor kinase or a b ARK inhibitor. Science 268, 1350-1353 (1995).
18. Ungerer M, Bohm M, Elce JS, Erdmann E, Lohse MJ. Altered expression of b-adrenergic receptor kinase and b 1-adrenergic receptors in the failing human heart. Circulation 87, 454-463 (1993). (Pubitemid 23040915)
19. Iaccarino G, Barbato E, Cipolletta E et al. Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. Eur. Heart J. 26, 1752-1758 (2005). (Pubitemid 41219848)
20. Hata JA, Williams ML, Schroder JN et al. Lymphocyte levels of GRK2 (bARK1) mirror changes in the LVAD-supported failing human heart: lower GRK2 associated with improved b-adrenergic signaling after mechanical unloading. J. Card. Fail. 12, 360-368 (2006). (Pubitemid 43817584)
21. Penela P, Murga C, Ribas C, Lafarga V, Mayor F Jr. The complex G protein-coupled receptor kinase 2 (GRK2) interactome unveils new physiopathological targets. Br. J. Pharmacol. 160, 821-832 (2010).
22. Rengo G, Lymperopoulos A, Zincarelli C et al. Myocardial adeno-associated virus serotype 6-bARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 119, 89-98 (2009).
23. Raake PW, Vinge LE, Gao E et al. G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ. Res. 103, 413-422 (2008).
24. White DC, Hata JA, Shah AS, Glower DD, Lefkowitz R, Koch WJ. Preservation of myocardial b-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. Proc. Natl Acad. Sci. USA 97, 5428-5433 (2000). (Pubitemid 30313735)
25. Bell RM, Yellon DM. There is more to life than revascularization: therapeutic targeting of myocardial ischemia/reperfusion injury. Cardiovasc. Ther. (2010) (Epub ahead of print).
26. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium: Circulation 74, 1124-1136 (1986). (Pubitemid 17174962)
27. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia reperfusion injury. Physiol. Rev. 88, 581-609 (2008). (Pubitemid 351520088)
28. Boucher M, Nim S, de Montigny C, Rousseau G. Alterations of b-adrenoceptor responsiveness in postischemic myocardium after 72 h of reperfusion. Eur. J. Pharmacol. 495, 185-191 (2004). (Pubitemid 38898743)
29. Chesley A, Lundberg MS, Asai T et al. The b(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3'-kinase. Circ. Res. 87, 1172-1179 (2000).
30. Liu S, Premont RT, Kontos CD, Huang J, Rockey DC. Endothelin-1 activates endothelial cell nitric-oxide synthase via heterotrimeric G-protein bg subunit signaling to protein kinase B/Akt. J. Biol. Chem. 278, 49929-49935 (2003). (Pubitemid 37548828)
31. Chen Y, Long H, Wu Z, Jiang X, Ma L. EGF transregulates opioid receptors through EGFR-mediated GRK2 phosphorylation and activation. Mol. Biol. Cell 19, 2973-2983 (2008).
32. Khoa ND, Postow M, Danielsson J, Cronstein BN. Tumor necrosis factor-a prevents desensitization of Gas-coupled receptors by regulating GRK2 association with the plasma membrane. Mol. Pharmacol. 69, 1311-1319 (2006).
33. Jurado-Pueyo M, Campos PM, Mayor F, Murga C. GRK2-dependent desensitization downstream of G proteins. J. Recept. Signal Transduct. Res. 28, 59-70 (2008). (Pubitemid 351588075)
34. Bulcao CF, Pandalai PK, D'Souza KM, Merrill WH, Akhter SA. Uncoupling of myocardial b-adrenergic receptor signaling during coronary artery bypass grafting: the role of GRK2. Ann. Thorac. Surg. 86, 1189-1194 (2008).
35. D'Souza KM, Malhotra R, Philip JL et al. G protein-coupled receptor kinase-2 is a novel regulator of collagen synthesis in adult human cardiac fibroblasts. J. Biol. Chem. 286, 15507-15516 (2011).
36. Brinks HL, Eckhart AD. Regulation of GPCR signaling in hypertension. Biochem. Biophys. Acta 1802, 1268-1275 (2010).
37. Obrenovich ME, Morales LA, Cobb CJ et al. Insights into cerebrovascular complications and Alzheimer disease through the selective loss of GRK2 regulation. J. Cell. Mol. Med. 13, 853-865 (2009).
38. Obrenovich ME, Smith MA, Siedlak SL et al. Overexpression of GRK2 in Alzheimer disease and in a chronic hypoperfusion rat model is an early marker of brain mitochondrial lesions. Neurotox. Res. 10, 43-56 (2006).
39. Suo Z, Wu M, Citron BA, Wong GT, Festoff BW. Abnormality of G-protein-coupled receptor kinases at prodromal and early stages of Alzheimer's disease: an association with early b-amyloid accumulation. J. Neurosci. 24, 3444-3452 (2004). (Pubitemid 38451910)
40. Rockman HA, Chien KR, Choi DJ et al. Expression of a b-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc. Natl Acad. Sci. USA 95, 7000-7005 (1998). (Pubitemid 28278096)
41. Shah AS, White DC, Emani S et al. In vivo ventricular gene delivery of a b-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation 103, 1311-1316 (2001). (Pubitemid 32221357)
42. Gwathmey JK, Yerevanian AI, Hajjar RJ. Cardiac gene therapy with SERCA2a: from bench to bedside. J. Mol. Cell Cardiol. 50(5), 803-812 (2011).
43. Muller OJ, Katus HA, Bekeredjian R. Targeting the heart with gene therapy-optimized gene delivery methods: Cardiovasc. Res. 73, 453-462 (2007). (Pubitemid 46084926)
44. Dib N, Menasche P, Bartunek JJ et al. Recommendations for successful training on methods of delivery of biologics for cardiac regeneration: a report of the International Society for Cardiovascular Translational research: JACC Cardiovasc. Interv. 3, 265-275 (2010).
45. Kamal FA, Smrcka AV, Blaxall BC. Taking the heart failure battle inside the cell: small molecule targeting of Gbg subunits. J. Mol. Cell Cardiol. (2011) (Epub ahead of print).
46. Casey LM, Pistner AR, Belmonte SL, et al. Small molecule disruption of Gbg signaling inhibits the progression of heart failure. Circ. Res. 107(4), 532-539 (2010).
47. Chan D, Ng LL. Biomarkers in acute myocardial infarction. BMC Med. 8, 34 (2010).
48. Sabatine MS, Morrow DA, de Lemos JA et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 105, 1760-1763 (2002). (Pubitemid 34408881)
49. Bonita RE, Raake PW, Otis NJ et al. Dynamic changes in lymphocyte GRK2 levels in cardiac transplant patients: a biomarker for left ventricular function. Clin. Transl. Sci. 3, 14-18 (2011).
50. Cohn HI, Xi Y, Pesant S et al. G protein-coupled receptor kinase 2 expression and activity are associated with blood pressure in black Americans. Hypertension 54, 71-76 (2009).
51. Santulli G, Campanile A, Spinelli L et al. G protein-coupled receptor kinase 2 in patients with acute myocardial infarction. Am. J. Cardiol. 107(8), 1125-1130 (2011).
52. Braunwald E. Reduction of myocardial-infarct size. N. Engl. J. Med. 291, 525-526 (1974).
53. Hausenloy DJ, Baxter G, Bell R et al. Translating novel strategies for cardioprotection: the hatter workshop recommendations. Basic Res. Cardiol. 105, 677-686 (2010).
54. Williams ML, Hata JA, Schroder J et al. Targeted b-adrenergic receptor kinase (bARK1) inhibition by gene transfer in failing human hearts. Circulation 109, 1590-1593 (2004). (Pubitemid 38451713)
55. Przyklenk K, Maynard M, Darling CE, Whittaker P. Aging mouse hearts are refractory to infarct size reduction with post-conditioning. J. Am. Coll. Cardiol. 51, 1393-1398 (2008). (Pubitemid 351443077)
56. Sivaraman V, Hausenloy DJ, Wynne AM, Yellon DM. Preconditioning the diabetic human myocardium. J. Cell. Mol. Med. 14, 1740-1746 (2010).
57. Przyklenk K, Maynard M, Greiner DL, Whittaker P. Cardioprotection with postconditioning. loss of efficacy in murine models of type-2 and type-1 diabetes. Antioxid. Redox Signal. 14, 781-790 (2011).
58. Harding VB, Jones LR, Lefkowitz RJ, Koch WJ, Rockman HA. Cardiac b ARK1 inhibition prolongs survival and augments b blocker therapy in a mouse model of severe heart failure. Proc. Natl Acad. Sci. USA 98, 5809-5814 (2001). (Pubitemid 32435724)